{"product_id":"imcr-five-forces","title":"(IMCR) Immunocore Holdings plc Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Immunocore Holdings plc Porter's Five Forces Analysis helps you understand the company’s competitive environment, including rivalry, buyer power, supplier power, substitutes, and new entrants. The page already shows a real preview of the actual report content, so you can see what you’re getting before buying. Purchase the full version for the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized biologics inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Immunocore Holdings plc’s T-cell receptor therapies still depend on GMP-qualified biologic reagents, cell-culture inputs, and controlled raw materials from a narrow vendor pool. That gives suppliers some leverage, because swapping a source can take 6-12 months for testing and requalification. Still, this power is capped by long-term supply controls and dual-sourcing where possible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on contract manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc depends on specialized CDMOs and GMP partners for biologics output, so supplier power stays high when capacity or batch release is tight. In this market, validation history and regulator track record often matter more than price, because a failed tech transfer or supply gap can delay clinical or commercial doses by quarters. That makes continuity a bigger bargaining lever than unit cost.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory-grade quality requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRegulatory-grade quality rules narrow Immunocore Holdings plc’s supplier pool because inputs for pharma and clinical use must meet GMP and GCP controls, so only a few vendors can qualify. A single batch-consistency or compliance failure can delay a trial cohort or shipment by weeks, which lifts incumbent supplier power. That matters even more when Immunocore is scaling its 2025 clinical and commercial supply chain under strict release testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eKey technology and assay providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc relies on specialized testing, analytics, and bioinformatics across oncology and infectious disease work, so key technology and assay vendors can have moderate leverage. When only a few providers can deliver validated potency, stability, and safety tools, switching costs rise and timelines can slip. One missed assay can delay a study by weeks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew validated vendors, higher leverage\u003c\/li\u003e\n\u003cli\u003eSpecialized assays raise switching costs\u003c\/li\u003e\n\u003cli\u003eCritical work can delay programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotentially moderate overall supplier power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces potentially moderate supplier power because it can spread risk across more than one vendor, but its precision manufacturing and strict GMP quality needs still narrow the field. In biotech, switching a qualified supplier is slow, so raw materials, specialty reagents, and contract manufacturing partners can still push on price and terms.\u003c\/p\u003e\n\u003cp\u003eThe company can soften that pressure with dual sourcing, long-term contracts, and tighter inventory planning, but supplier leverage does not disappear. For a complex biologics model, even small disruptions can affect batch release timing, so supplier power stays meaningful rather than weak.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNot locked to one supplier base\u003c\/li\u003e\n\u003cli\u003ePrecision manufacturing limits alternatives\u003c\/li\u003e\n\u003cli\u003eGMP rules make switching slow\u003c\/li\u003e\n\u003cli\u003eDual sourcing can reduce risk\u003c\/li\u003e\n\u003cli\u003eSupplier power stays moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore’s Supplier Power Stayed Moderate in FY2025\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn FY2025, Immunocore Holdings plc’s supplier power stayed moderate because GMP-qualified reagents, specialty analytics, and CDMO capacity come from a narrow vendor base. Switching can take 6-12 months, so continuity and validation history matter more than price. Long-term contracts and dual sourcing help, but they do not remove the bottleneck.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching time\u003c\/td\u003e\n\u003ctd\u003e6-12 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier pool\u003c\/td\u003e\n\u003ctd\u003eNarrow, GMP-limited\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePower level\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses Immunocore Holdings plc’s competitive pressures, supplier and buyer power, new entrants, and substitutes shaping profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA quick, investor-ready view of Immunocore’s five competitive forces—ideal for faster biotech strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eShows the credible sources behind key claims, making the Immunocore Holdings plc reference trail easy to verify and use in decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and specialist prescriber influence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKIMMTRAK’s uptake is driven by oncologists, specialty centers, and protocol-based care, so buyers have real leverage over prescribing. In 2025, Immunocore still relied on one marketed product, which makes formulary access and clinical preference especially important. Because treatment sits in concentrated specialist pathways, hospital and prescriber power stays high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer and reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInsurers and national health systems can set prior auth, step edits, and price caps, so Immunocore Holdings plc may not realize list price even when clinical need is high. Uveal melanoma is rare, at about 5,000 new U.S. cases a year, which gives payers more leverage on net price than on volume. NICE and other HTA bodies can also block or delay access unless discounts and evidence packages are strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall patient population reduces volume power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eUveal melanoma is rare, at about 5-7 cases per million people each year, so Immunocore Holdings plc sells to a small patient pool. That limits any one buyer’s ability to push for deep volume discounts. Still, most demand runs through a few specialist cancer centers and payers, so those channels can keep real negotiating power over price and access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical value supports pricing power\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKIMMTRAK’s clinical benefit reduces customer pushback: in the phase 3 trial, median overall survival was 21.6 months versus 16.9 months with investigator’s choice, so buyers have less room to substitute or demand deep discounts. Uveal melanoma is rare, with about 5,000 cases a year in the U.S., and that unmet need supports premium pricing. That still only partly offsets buyer power.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e21.6 vs 16.9 months median OS\u003c\/li\u003e\n\u003cli\u003eRare cancer limits alternatives\u003c\/li\u003e\n\u003cli\u003ePremium pricing is easier to defend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOverall buyer power is moderate to high\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOverall buyer power is moderate to high. Immunocore Holdings plc sells to specialist hospitals and sophisticated payers that demand strong clinical and health-economics evidence, so they can shape market access, price, and where a therapy sits in treatment lines.\u003c\/p\u003e\n\u003cp\u003eThat pressure is stronger beyond early adopters, where reimbursement rules matter more than science alone. In Immunocore Holdings plc’s 2025 reporting cycle, KIMMTRAK remained the key revenue driver, so payer pushback on one product can still move the whole base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSpecialist buyers set evidence hurdles\u003c\/li\u003e\n\u003cli\u003ePayers influence price and access\u003c\/li\u003e\n\u003cli\u003eTreatment placement can be restricted\u003c\/li\u003e\n\u003cli\u003ePower rises outside early adopters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist Buyers Hold Strong Leverage Over KIMMTRAK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCustomer power is moderate to high for Immunocore Holdings plc because KIMMTRAK is sold through a small set of specialist centers and payers that can control access, prior auth, and net price. In 2025, one-product dependence made that leverage matter more. Rare uveal melanoma, about 5,000 U.S. cases a year, limits volume but not buyer pressure.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. uveal melanoma cases\u003c\/td\u003e\n\u003ctd\u003e~5,000\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead product\u003c\/td\u003e\n\u003ctd\u003eKIMMTRAK\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer set\u003c\/td\u003e\n\u003ctd\u003eSpecialists, payers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBuyer power\u003c\/td\u003e\n\u003ctd\u003eModerate to high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eImmunocore Holdings plc Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Immunocore Holdings plc Porter's Five Forces Analysis you’ll receive after purchase—no samples, no placeholders. The document is fully written, professionally formatted, and ready to use immediately. What you see here is the complete deliverable, so once you buy, you get instant access to this same file.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocused oncology competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore faces intense rivalry in oncology, where large biopharma and fast biotech teams chase the same unmet needs with novel immunotherapies. Even with differentiated TCR science, the fight is crowded: oncology R\u0026amp;D spending across the industry stayed near record highs in 2025, and rivals keep pushing into the same melanoma, solid tumor, and rare cancer niches. That makes pricing, data wins, and trial speed critical.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlatform race in T-cell engagers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces intense platform race pressure because its T-cell receptor approach competes with bispecific and other T-cell redirecting systems in solid tumors. KIMMTRAK remains the first and only approved T-cell receptor therapy in metastatic uveal melanoma, but rivals keep pushing better efficacy, safety, and dosing convenience. That constant innovation race raises the bar for every new trial and label expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePipeline breadth increases overlap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces tighter rivalry because two lead solid-tumor programs, IMC-C103C and IMC-F106C, broaden its overlap across NSCLC, ovarian, breast, and melanoma. These are among the same high-traffic oncology arenas where rivals already have late-stage assets, so head-to-head trial competition is intense. In 2025, oncology still drew the largest share of biotech R\u0026amp;D and deal value, which keeps pressure high. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial stage but limited marketed footprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eKIMMTRAK gives Immunocore Holdings plc a real commercial base, but it still sells into one rare niche: metastatic uveal melanoma, a disease with only about 3,000 U.S. cases a year. That leaves the revenue base narrow, so Immunocore Holdings plc is not yet protected by a broad franchise. Bigger rivals with wider labels, deeper sales teams, or faster launch scale can still pressure future growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne marketed drug, one main rare indication\u003c\/li\u003e\n\u003cli\u003eSmall patient pool limits revenue breadth\u003c\/li\u003e\n\u003cli\u003eBroader competitors can outscale launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCompetitive rivalry is high\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCompetitive rivalry is high because biotech winners are set by patent life, Phase 2\/3 readouts, and fast physician adoption. For Immunocore Holdings plc, the key test is proving clear clinical differentiation for KIMMTRAK, its only marketed drug, in HLA-A*02:01-positive uveal melanoma.\u003c\/p\u003e\n\u003cp\u003eIn this sector, one positive data release can quickly pull investor and partner attention away from rivals, so pricing power and pipeline value can shift fast. That makes rivalry intense for Immunocore Holdings plc, since its growth depends on beating other oncology immunotherapy programs on efficacy, safety, and label expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatent timing drives biotech share gains.\u003c\/li\u003e\n\u003cli\u003eClinical readouts can reprice stocks fast.\u003c\/li\u003e\n\u003cli\u003eKIMMTRAK is Immunocore Holdings plc's anchor asset.\u003c\/li\u003e\n\u003cli\u003eSuperior differentiation is the main moat.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore Faces Fierce Rivalry in a Tiny, Fast-Moving Oncology Niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for Immunocore Holdings plc because KIMMTRAK competes in a crowded oncology market where large biopharma and biotech groups are chasing the same solid-tumor targets. KIMMTRAK is still the only approved T-cell receptor therapy for metastatic uveal melanoma, but its moat is narrow because U.S. incidence is only about 3,000 cases a year. New data, faster trials, and cleaner safety can quickly shift share.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eRivalry driver\u003c\/th\u003e\n\u003cth\u003eLatest signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKIMMTRAK market\u003c\/td\u003e\n\u003ctd\u003eOnly approved TCR therapy; ~3,000 U.S. cases\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline overlap\u003c\/td\u003e\n\u003ctd\u003eNSCLC, ovarian, breast, melanoma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetition factor\u003c\/td\u003e\n\u003ctd\u003eEfficacy, safety, label expansion, speed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting standard oncology therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSurgery, radiation, chemotherapy, and established systemic regimens still anchor first-line care across many cancers, so they remain strong substitutes for Immunocore Holdings plc’s newer immunotherapies. The pressure is highest where these options are cheaper, off-patent, and familiar to oncologists, especially in a market serving about 20 million new cancer cases a year worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCheckpoint inhibitors and other immunotherapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCheckpoint blockade and other immunotherapies are strong substitutes for Immunocore Holdings plc in solid tumors. Merck’s Keytruda generated about $29.5 billion in 2024 sales, and Bristol Myers Squibb’s Opdivo brought in about $9.3 billion, showing how entrenched these options are. If an ADC or biologic has better efficacy or simpler dosing, physicians can shift fast and weaken demand for new entrants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and gene therapy alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCell and gene therapy alternatives raise the substitute threat because CAR-T, gene-modified cells, and other engineered therapies target the same high-value oncology niches that Immunocore Holdings plc serves. They are not direct swaps, but they can still pull clinical focus and capital away; in 2025, that kind of portfolio shift mattered as buyers favored platforms with broader tumor data and faster response rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRare disease treatment options are limited but evolving\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor uveal melanoma, direct substitutes are still scarce, which helps KIMMTRAK hold a strong niche. In the Phase 3 trial, KIMMTRAK delivered median overall survival of 21.7 months versus 16.0 months for control, showing why switching costs are high. Still, the field can shift fast if a new therapy beats this efficacy or improves safety. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew direct substitutes in uveal melanoma\u003c\/li\u003e\n\u003cli\u003eKIMMTRAK OS: 21.7 months vs 16.0 months\u003c\/li\u003e\n\u003cli\u003eBetter future data could pressure demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eThreat of substitutes is moderate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces a moderate threat from substitutes because its T-cell receptor platform and targeted mechanism are differentiated, but patients and physicians can still choose from many oncology options, including checkpoint inhibitors, bispecifics, antibody-drug conjugates, and CAR-T. In 2025, this wide treatment pool kept switching pressure alive even where Company Name’s science is strong.\u003c\/p\u003e\n\u003cp\u003eThe threat stays moderate, not low, because alternative therapies exist across most target areas and payers still compare outcomes and cost. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDifferentiated TCR platform\u003c\/li\u003e\n\u003cli\u003eMany oncology substitutes exist\u003c\/li\u003e\n\u003cli\u003eSwitching pressure remains real\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eModerate substitute risk as KIMMTRAK holds a niche edge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes for Immunocore Holdings plc is moderate: surgery, radiation, chemotherapy, checkpoint blockers, ADCs, bispecifics, and CAR-T all compete for the same oncology budgets. KIMMTRAK still has a niche in uveal melanoma, where median overall survival was 21.7 months versus 16.0 months in control, but payer and physician switching pressure stays real.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCheckpoint inhibitors\u003c\/td\u003e\n\u003ctd\u003eKeytruda sales: $29.5bn in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUveal melanoma\u003c\/td\u003e\n\u003ctd\u003eKIMMTRAK OS: 21.7 vs 16.0 months\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh scientific barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces a low threat from new entrants because biologic drug discovery needs rare skills in immunology, protein engineering, and translational medicine. Its TCR platform took years to build and validate, and it already has an approved product, KIMMTRAK, which raised the scientific bar for rivals. New firms must clear a long learning curve and heavy R\u0026amp;D spend before they can match this depth.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy capital and time requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore Holdings plc faces a steep entry barrier because clinical development, manufacturing scale-up, and launch can take 6-8 years and cost tens of millions per program. Only about 1 in 10 drug candidates that enter clinical testing reaches approval, so late-stage failure risk is high. That scale of spend and risk keeps smaller biotech entrants out unless they have deep funding or a strong partner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and safety hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNew immune-oncology drugs face a high bar: they must clear Phase I-III trials and years of FDA or EMA review, often taking 6-10 years before launch. In 2025\/2026, this is even tougher in immune-based oncology, where off-target effects can be severe and safety monitoring is strict, so easy market entry stays unlikely.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIP and know-how create protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore Holdings plc’s proprietary TCR platform, patent estate, and years of clinical data make direct imitation hard. New entrants can chase other immunology routes, but copying the same binding logic and evidence base is costly and slow. That IP wall lowers new-entrant pressure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePatents protect core platform know-how.\u003c\/li\u003e\n\u003cli\u003eClinical data raises replication cost.\u003c\/li\u003e\n\u003cli\u003eAlternative approaches are not direct copies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eThreat of new entrants is moderate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThreat of new entrants is moderate. Biotech still attracts start-ups, but Immunocore Holdings plc’s mix of T-cell receptor science, costly clinical work, and tight regulation is hard to copy; in 2025, the company still had only 1 approved product, which shows how steep the bar is.\u003c\/p\u003e\n\u003cp\u003eLarge pharma can still join through deals or M\u0026amp;A, so entry is possible, but de novo rivals face years of R\u0026amp;D and nine-figure trial spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eScience barrier stays high\u003c\/li\u003e\n\u003cli\u003eCapital needs are huge\u003c\/li\u003e\n\u003cli\u003eDeals beat greenfield entry\u003c\/li\u003e\n\u003cli\u003eThreat stays moderate\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmunocore’s Entry Barriers Stay High Despite Big Pharma Interest\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Immunocore Holdings plc stays low. A rival would need rare TCR science, 6-10 years of development and review, and heavy funding, while only about 1 in 10 clinical candidates reaches approval.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIP and data\u003c\/td\u003e\n\u003ctd\u003eHard to copy KIMMTRAK and platform know-how\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapital\u003c\/td\u003e\n\u003ctd\u003eLate-stage trials can cost nine figures\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProof\u003c\/td\u003e\n\u003ctd\u003eOnly 1 approved product in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eBig pharma can enter by deal or M\u0026amp;A, but greenfield entry remains tough.\u003c\/p\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234565366025,"sku":"imcr-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/imcr-five-forces.webp?v=1785721794","url":"https:\/\/dcfanalyst.com\/products\/imcr-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}